logo

For the Inventor, By the Inventor

Huddinge, Sweden

Medivir Ab


USPTO Granted Patents = 120

% Expired Patents = 47.5



Trademarks = 1

Forward Citations = 820

Loading Chart...
Loading Chart...

184 inventors (with patents filed for the assignee):

goldMedal Pierre Jean-Marie Bernard Raboisson (20 out of 178 patents)

silverMedal Bengt Bertil Samuelsson (20 out of 24 patents)

bronzeMedal Bertil Samuelsson (17 out of 17 patents)

4.  Åsa Annica Kristina Rosenquist (16 out of 18 patents)

5.  Karl Magnus Nilsson (16 out of 18 patents)

6.  Urszula Grabowska (14 out of 18 patents)

7.  Kenneth Simmen (14 out of 26 patents)

8.  Xiao-Xiong Zhou (14 out of 14 patents)

9.  Magnus Nilsson (13 out of 14 patents)

10.  Pia Kahnberg (13 out of 18 patents)

11.  Herman Augustinus De Kock (13 out of 36 patents)

12.  Abdellah Tahri (12 out of 61 patents)

13.  Lili Hu (12 out of 37 patents)

14.  Nils-Gunnar Johansson (12 out of 12 patents)

15.  Hans Kristian Wallberg (12 out of 16 patents)


Core Competencies:
Cysteine Protease Inhibitors
HCV Polymerase Inhibitors
Antiviral Nucleosides
Dioxolane Nucleotides
Macrocyclic Inhibitors
Protease Inhibitors
Histone Deacetylase Inhibitors
Leukemia Therapy

120 patents:

1. 12479870 - Base-modified cytidine nucleotides for leukemia therapy (2025-11-25),
2. 12378209 - Protease inhibitors (2025-08-05),
3. 12303521 - Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibody (2025-05-20),
4. 12221459 - Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides (2025-02-11),
5. 11951147 - SMAC mimetic (2024-04-09),
6. 11607399 - Pharmaceutical formulation for histone deacetylase inhibitors (2023-03-21),
7. 11447511 - Dioxolane analogues of uridine for the treatment of cancer (2022-09-20),
8. 11351221 - SMAC mimetic (2022-06-07),
9. 11312693 - Protease inhibitors (2022-04-26),
10. 10822360 - Dioxolane analogues of uridine for the treatment of cancer (2020-11-03),
11. 10723709 - Protease inhibitors (2020-07-28),
12. 10654877 - Dioxolane analogues of uridine for the treatment of cancer (2020-05-19),
13. 10596220 - SMAC mimetic (2020-03-24),
14. 10336780 - Dioxolane analogues of uridine for the treatment of cancer (2019-07-02),
15. 10329266 - Protease inhibitors (2019-06-25),
Medivir AB, based in Huddinge, Sweden, is a biopharmaceutical company focused on developing innovative cancer therapeutics. The company specializes in a range of core technologies, including cysteine protease inhibitors and antiviral nucleosides, aimed at addressing unmet medical needs in oncology and viral infections. Medivir's research encompasses various therapeutic areas, including leukemia therapy and the development of macrocyclic inhibitors, positioning it as a key player in the advancement of targeted treatments.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Medivir Ab
120 Patents

#1 in Huddinge

#67 in Sweden

#6,637 in the World

Huddinge, SE
Huddinge, Sweden

Medivir Ab

Forward Citations = 820

184 inventors:

goldMedal Pierre Jean-Marie Bernard Raboisson (20 out of 178 patents)

silverMedal Bengt Bertil Samuelsson (20 out of 24 patents)

bronzeMedal Bertil Samuelsson (17 out of 17 patents)

4.  Åsa Annica Kristina Rosenquist (16 out of 18 patents)

5.  Karl Magnus Nilsson (16 out of 18 patents)

Please report any incorrect information to [email protected]
Loading…